Reed Ac Siemieniuk1, Brenda Beckthold2, M John Gill3. 1. Southern Alberta HIV Clinic, Calgary, Alberta; ; Department of Medicine, University of Toronto, Toronto, Ontario; 2. Southern Alberta HIV Clinic, Calgary, Alberta; 3. Southern Alberta HIV Clinic, Calgary, Alberta; ; Department of Microbiology, Immunology & Infectious Diseases, University of Calgary, Calgary, Alberta.
Abstract
BACKGROUND: HIV-1 is a highly diverse virus; subtypes may exhibit differences in rates of transmission, disease progression, neurotoxicity, antiretroviral treatment failure profiles and accuracy of viral load measurements. To date, the HIV epidemic in Canada and the rest of the developed world has been largely due to subtype B; however, shifts in subtype epidemiology could have significant implications. OBJECTIVE: To determine whether there has been an increase in HIV subtype diversity in southern Alberta, Canada. METHODS: All 2358 patients receiving any HIV care between December 31, 2001 and December 31, 2010 were included in a retrospective analysis of subtype prevalence and incidence. In an indexed analysis, subtype trends from 1994 to 2010 were also evaluated. RESULTS: Between 2001 and 2010, the prevalence of non-B HIV subtypes in patients with a known subtype increased from 7% to 24%. In 2010, the most prevalent non-B subtypes were C (65%), A (11%), CRF02_AG (9.7%), CRF01_AE (4.9%), D (3.9%), G (2.9%) and CRF06_cpx (1.5%). In the indexed analysis, there was an overall proportional increase in non-B subtypes of 2.3% per year. The year-over-year increase in the prevalence of patients infected with a nonsubtype B virus increased from 13% from 1995 to 2002 to 27% from 2003 to 2010 (P=0.01). Incident non-B subtype cases increased from 9.6% to 32.4% over these time periods. CONCLUSIONS: This recent and dramatic shift in HIV strain diversity in Canada is unprecedented and may have important public health, research and clinical consequences.
BACKGROUND:HIV-1 is a highly diverse virus; subtypes may exhibit differences in rates of transmission, disease progression, neurotoxicity, antiretroviral treatment failure profiles and accuracy of viral load measurements. To date, the HIV epidemic in Canada and the rest of the developed world has been largely due to subtype B; however, shifts in subtype epidemiology could have significant implications. OBJECTIVE: To determine whether there has been an increase in HIV subtype diversity in southern Alberta, Canada. METHODS: All 2358 patients receiving any HIV care between December 31, 2001 and December 31, 2010 were included in a retrospective analysis of subtype prevalence and incidence. In an indexed analysis, subtype trends from 1994 to 2010 were also evaluated. RESULTS: Between 2001 and 2010, the prevalence of non-B HIV subtypes in patients with a known subtype increased from 7% to 24%. In 2010, the most prevalent non-B subtypes were C (65%), A (11%), CRF02_AG (9.7%), CRF01_AE (4.9%), D (3.9%), G (2.9%) and CRF06_cpx (1.5%). In the indexed analysis, there was an overall proportional increase in non-B subtypes of 2.3% per year. The year-over-year increase in the prevalence of patients infected with a nonsubtype B virus increased from 13% from 1995 to 2002 to 27% from 2003 to 2010 (P=0.01). Incident non-B subtype cases increased from 9.6% to 32.4% over these time periods. CONCLUSIONS: This recent and dramatic shift in HIV strain diversity in Canada is unprecedented and may have important public health, research and clinical consequences.
Authors: D L Robertson; J P Anderson; J A Bradac; J K Carr; B Foley; R K Funkhouser; F Gao; B H Hahn; M L Kalish; C Kuiken; G H Learn; T Leitner; F McCutchan; S Osmanov; M Peeters; D Pieniazek; M Salminen; P M Sharp; S Wolinsky; B Korber Journal: Science Date: 2000-04-07 Impact factor: 47.728
Authors: Jean-Christophe Plantier; Marie Leoz; Jonathan E Dickerson; Fabienne De Oliveira; François Cordonnier; Véronique Lemée; Florence Damond; David L Robertson; François Simon Journal: Nat Med Date: 2009-08-02 Impact factor: 53.440
Authors: Grace C John-Stewart; Ruth W Nduati; Christine M Rousseau; Dorothy A Mbori-Ngacha; Barbra A Richardson; Stephanie Rainwater; Dana D Panteleeff; Julie Overbaugh Journal: J Infect Dis Date: 2005-06-23 Impact factor: 5.226
Authors: Jared M Baeten; Bhavna Chohan; Ludo Lavreys; Vrasha Chohan; R Scott McClelland; Laura Certain; Kishorchandra Mandaliya; Walter Jaoko; Julie Overbaugh Journal: J Infect Dis Date: 2007-03-02 Impact factor: 5.226
Authors: M Thomas P Gilbert; Andrew Rambaut; Gabriela Wlasiuk; Thomas J Spira; Arthur E Pitchenik; Michael Worobey Journal: Proc Natl Acad Sci U S A Date: 2007-10-31 Impact factor: 11.205
Authors: Robert H Paul; John A Joska; Carol Woods; Soraya Seedat; Susan Engelbrecht; Jacqueline Hoare; Jodi Heaps; Victor Valcour; Beau Ances; Laurie M Baker; Lauren E Salminen; Dan J Stein Journal: J Neurovirol Date: 2014-11-01 Impact factor: 2.643
Authors: Fredrick H Omondi; Sandali Chandrarathna; Shariq Mujib; Chanson J Brumme; Steven W Jin; Hanwei Sudderuddin; Rachel L Miller; Asa Rahimi; Oliver Laeyendecker; Phil Bonner; Feng Yun Yue; Erika Benko; Colin M Kovacs; Mark A Brockman; Mario Ostrowski; Zabrina L Brumme Journal: J Virol Date: 2019-03-05 Impact factor: 5.103
Authors: Zehava Grossman; Sheryl-Vi Rico; Katherine Cone; Wei Shao; Catherine Rehm; Sara Jones; Giorgio Bozzi; Sophie Dean; Robin Dewar; Tauseef Rehman; Julia Purdy; Colleen Hadigan; Alice K Pau; Frank Maldarelli Journal: AIDS Res Hum Retroviruses Date: 2018-08 Impact factor: 2.205
Authors: Kobus J Bosman; Annemarie Mj Wensing; Aster E Pijning; Wilco J van Snippenberg; Petra M van Ham; Dorien Mc de Jong; Andy Im Hoepelman; Monique Nijhuis Journal: J Int AIDS Soc Date: 2018-09 Impact factor: 5.396